Cipla secures USFDA’s approval for AIDS treatment drug nevirapine

03 May 2012 Evaluate

Cipla, one of the world’s leading generic pharmaceutical companies in collaboration with Drugs for Neglected Diseases Initiative (DNDi) has received US Food and Drug Administration’s (USFDA) approval for acquired immune deficiency syndrome (AIDS) treatment drug nevirapine. The drug is a generic version of German drug-maker Boehringer Ingelheim's Viramune tablets.

Recently, the company had announced that it is planning to launch the Fixed-Dose combination of ‘Artesunate (AS) 1 + Mefloquine (MQ) 2’ for the treatment of uncomplicated P. falciparum malaria. The combination of AS and MQ is proven to be a safe, rapid and reliably effective treatment for uncomplicated P. falciparum malaria and is recommended by the World Health Organization (WHO).

Cipla Share Price

1314.85 -56.70 (-4.13%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×